John Mark Tohlen, MD
Family Medicine · Corinth, TXNPI 1598298077
Payments from drug & device makers
Across 80 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$200
- AstraZeneca$142
- Astellas Pharma US Inc$122
- Biohaven Pharmaceuticals, Inc.$64
- Amarin Pharma, Inc.$64
- Novo Nordisk$55
- plus $564 from 21 others
What the payments were for
- Food & beverage$1,210100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $200 |
| AstraZeneca | 9 | $142 |
| Astellas Pharma US Inc | 9 | $122 |
| Biohaven Pharmaceuticals, Inc. | 4 | $64 |
| Amarin Pharma, Inc. | 5 | $64 |
| Novo Nordisk | 4 | $55 |
| Merck | 3 | $51 |
| Novartis | 3 | $50 |
| Pfizer | 2 | $50 |
| Amgen | 3 | $49 |
| Lilly USA, LLC | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Genentech USA, Inc. | 2 | $33 |
| GSK | 2 | $30 |
| Exact Sciences | 1 | $29 |
| Johnson & Johnson | 2 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Bayer | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,210 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 29 | $373 |
| Pantoprazole Sodium | 30 | $344 |
| Rosuvastatin Calcium | 30 | $296 |
| Levothyroxine Sodium | 28 | $273 |
| Lisinopril | 27 | $246 |
| Atorvastatin Calcium | 18 | $143 |
| Omeprazole | 16 | $109 |
| Trazodone Hcl | 13 | $37 |
| Hydrochlorothiazide | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Corinth
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.